Anti-PD-1 and PD-L1 antibodies demonstrated remarkable efficacy across a wide spectrum of malignancies, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, head and neck cancers, and urothelial carcinoma [2]. Here, CD274 is linked to renal cell carcinoma.